10-Q: MoonLake Immunotherapeutics Reports Mixed Phase 3 HS Results

MoonLake Immunotherapeutics reported increased losses and mixed Phase 3 hidradenitis suppurativa trial results, impacting its debt facility, while advancing other clinical programs.

Summary

• Net loss for the nine months ended September 30, 2025, significantly increased to $167.3 million, up from $74.8 million in the prior year.
• Research and development expenses more than doubled to $146.9 million for the nine months ended September 30, 2025, driven by increased clinical trial activity and manufacturing.
• General and administrative expenses rose to $32.8 million for the nine months ended September 30, 2025, supporting organizational growth and pre-commercial activities.
• Cash, cash equivalents, and short-term marketable securities totaled $380.5 million as of September 30, 2025, projected to fund operations into the second half of 2027.
• The VELA-1 Phase 3 study for hidradenitis suppurativa (HS) met its primary endpoint, but VELA-2 did not due to a higher-than-expected placebo response.
• Failure to meet the Tranche 2 Milestone due to VELA-2's results reduced the available Credit Facility by $175.0 million.
• Positive results were reported for the LEDA clinical trial in palmoplantar pustulosis (PPP), with a mean PPPASI change of 64% at week 16.
• An interim analysis of the VELA-TEEN trial in adolescent HS showed 46% of patients achieved HiSCR75 response at week 16.
• A class action lawsuit, Peters v. MoonLake Immunotherapeutics, et al., was filed alleging false or misleading statements related to sonelokimab's clinical benefits.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant increase in net loss, the failure of one of the two pivotal Phase 3 HS trials (VELA-2) to meet its primary endpoint, and the subsequent reduction in available debt financing. While other clinical programs show promise and VELA-1 was positive, the setback in VELA-2 for the lead indication is a material negative event, compounded by ongoing legal proceedings.

Positives

• VELA-1 Phase 3 study for hidradenitis suppurativa (HS) achieved statistical significance for all primary and key secondary endpoints (HiSCR75, delta to placebo of 17%, p<0.001).
• The combined VELA program demonstrated clinically meaningful and statistically significant improvement across all primary and key secondary endpoints (p<0.001).
• LEDA clinical trial in palmoplantar pustulosis (PPP) showed promising results, with patients achieving a mean percent change from baseline in PPPASI of 64% at week 16, and 39% achieving PPPASI75.
• Interim analysis of the VELA-TEEN trial in adolescent HS showed 46% of patients achieved a HiSCR75 response at week 16.
• Successful end-of-Phase 2 interactions with both the U.S. FDA and E.U. EMA for the PsA program, supporting the proposed Phase 3 approach.
• Cash, cash equivalents, and short-term marketable securities of $380.5 million are expected to fund operations into the second half of 2027.
• The company was in compliance with all covenants of its Loan and Security Agreement as of September 30, 2025.

Negatives

• Net loss for the nine months ended September 30, 2025, increased by 123.5% to $167.3 million from $74.8 million in the prior year.
• Research and development expenses increased by 102.8% to $146.9 million for the nine months ended September 30, 2025.
• General and administrative expenses increased by 55.3% to $32.8 million for the nine months ended September 30, 2025.
• VELA-2 Phase 3 study for hidradenitis suppurativa (HS) did not achieve statistical significance in its week 16 primary endpoint (HiSCR75, delta to placebo of 9%, p=0.053) due to a higher-than-expected placebo response.
• The failure of VELA-2 to meet its primary endpoint resulted in not achieving the Tranche 2 and Tranche 4 Milestones of the Credit Facility, reducing the committed amount by $175.0 million.
• A class action lawsuit, Peters v. MoonLake Immunotherapeutics, et al., was filed alleging false or misleading statements related to sonelokimab's clinical benefits and prospects.

Risks

• Ability to obtain future financing.
• Regulatory approval and market acceptance of, and reimbursement for, product candidates.
• Performance of third-party contract research organizations and manufacturers.
• Protection of intellectual property.
• Litigation or claims based on intellectual property, patent, product, regulatory, clinical, or other factors.
• Ability to attract and retain employees necessary to support growth.
• Dependence on a small number of manufacturers for active pharmaceutical ingredients and formulated drugs.
• Uncertainty of generating revenue sufficient to achieve profitability, dependent on successful development and commercialization of SLK.
• Significant expenses and operating losses expected for at least the next two to three years.
• Fluctuating operating losses depending on timing of clinical development programs and regulatory approval efforts.
• Potential impact of adverse business and economic conditions, including inflationary pressures, general economic slowdown or recession, fluctuating interest rates, new or increased tariffs, and changes in fiscal and monetary policy.
• Inability to raise additional capital when needed or on acceptable terms, potentially forcing delays, reductions, or elimination of development programs or commercialization efforts.
• Risk of unexpected results from clinical trials, leading to discontinuation, delay, or modification of trials.
• Potential for delays or additional requirements from regulatory authorities (FDA, EMA) for clinical trials or testing.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for at least the next three years as it develops Sonelokimab (SLK) and prepares for commercial launches. A first Biologics License Application (BLA) for SLK is expected to be submitted in the third or fourth quarter of 2026, with a potential first commercial launch in the U.S. in 2027, subject to FDA approval. The company anticipates needing additional capital to commercialize SLK and develop future product candidates, expecting to finance these needs through equity, debt, or product collaborations. One-year data for the VELA-1 and VELA-2 trials is expected in Q2 2026, IZAR-1 readout in Q2 2026, IZAR-2 readout in H2 2026, S-OLARIS results in Q1 2026, and topline VELA-TEEN results in Q2 2026. A Phase 3 clinical trial in PPP is expected to commence in Q3 2026.

Management Comments

• "Based on our current operating plan and the Loan and Security Agreement... management believes that the Company has sufficient capital to fund its operations and capital expenditures into the second half of 2027."
• "We expect to continue to incur significant expenses and operating losses for at least the next three years as we continue the development of SLK and prepare for commercial launches."
• "We expect to submit a first BLA for SLK in the third or fourth quarter of 2026 and, subject to FDA approval, a first commercial launch in the U.S. in 2027."

Industry Context

MoonLake Immunotherapeutics operates as a single-asset clinical stage biotechnology company, focusing on Sonelokimab (SLK) for inflammatory skin and joint diseases. The company's strategy to develop SLK across multiple indications (HS, PsA, PPP, axSpA) aligns with a broader industry trend of maximizing the potential of novel therapeutic mechanisms. The mixed Phase 3 results for HS highlight the inherent risks and unpredictability of late-stage clinical development in the biopharmaceutical sector, where high placebo responses can significantly impact trial outcomes. The ongoing need for substantial capital to fund clinical trials and prepare for commercialization is typical for companies at this stage, especially those without approved products or revenue streams. The legal challenges faced by the company, alleging misleading statements, underscore the increased scrutiny and litigation risk in the biotech industry, particularly following significant clinical trial announcements.

Comparison to Industry Standards

• The company's reliance on a single asset, Sonelokimab (SLK), is a common strategy for early to mid-stage biotech companies, similar to how companies like Argenx focused initially on efgartigimod or Alnylam on patisiran, before diversifying.
• The reported HiSCR75 delta to placebo of 17% for VELA-1 is a strong result, comparable to or exceeding some approved therapies in HS, such as Humira (adalimumab) which showed HiSCR50 rates around 40-50% in its pivotal trials, or Cosentyx (secukinumab) which achieved HiSCR75 rates of 45-55% in its Phase 3 trials. However, direct comparison requires considering different trial designs and patient populations.
• The higher-than-expected placebo response in VELA-2, which led to the failure to meet the primary endpoint, is a known challenge in inflammatory disease trials, seen in studies for other drugs like AbbVie's Skyrizi (risankizumab) or Eli Lilly's Taltz (ixekizumab) in various dermatological indications, where placebo responses can vary significantly across trials.
• The positive results for the LEDA trial in PPP, with a mean PPPASI change of 64% and 39% achieving PPPASI75, suggest a strong efficacy signal. This is competitive with existing treatments like Tremfya (guselkumab) which showed PPPASI75 rates around 30-40% in its Phase 3 trials for PPP.
• The company's cash runway into the second half of 2027, with $380.5 million in cash and marketable securities, is a reasonable timeframe for a clinical-stage biotech, but the reduction in available debt tranches due to clinical trial outcomes is a direct consequence of performance, a common feature in milestone-based financing agreements in the industry.

Legal Proceedings

• On October 15, 2025, a lawsuit captioned Bridgewood v. MoonLake Immunotherapeutics, et al., Case No. 1:25-cv-8500, was filed in the United States District Court for the Southern District of New York, naming the Company, its Chief Executive Officer, and its Chief Financial Officer as defendants. The lawsuit alleged claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, based on allegedly false or misleading statements related to the clinical benefits and prospects of sonelokimab. This action was voluntarily dismissed without prejudice on October 22, 2025.
• On October 17, 2025, a second putative class action captioned Peters v. MoonLake Immunotherapeutics, et al., Case No. 1:25-cv-8612, was filed in the United States District Court for the Southern District of New York. This lawsuit names the same defendants, contains identical allegations of alleged violations of the Exchange Act, and seeks the same relief as the Bridgewood Action. The company denies the allegations and intends to vigorously defend against the claims. The ultimate outcome and potential loss cannot be estimated.

Stakeholder Impact

• **Shareholders:** The mixed Phase 3 results for VELA-2 and the reduction in available debt tranches could lead to increased share price volatility and potential dilution if future capital raises are equity-based. The ongoing class action lawsuit also presents a risk.
• **Employees:** Continued investment in R&D and organizational growth suggests stable to increasing employment opportunities, particularly in clinical, scientific, and administrative roles. Share-based compensation plans are in place to attract and retain talent.
• **Customers (Future Patients):** The positive results from VELA-1, ARGO, LEDA, and VELA-TEEN suggest potential future treatment options for various inflammatory diseases, offering hope for unmet medical needs, despite the VELA-2 setback.
• **Creditors:** The company remains in compliance with all covenants of its Loan and Security Agreement, providing some assurance, but the reduction in available tranches due to clinical milestones not being met could be a concern for future debt financing.
• **Suppliers/CROs/CMOs:** Increased R&D spending and committed expenses indicate continued engagement and business for contract research and manufacturing organizations.

Next Steps

• Seek FDA input on the adequacy of the current clinical evidence package to support a Biologics License Application (BLA) submission for SLK in HS around the end of 2025.
• Expect 1-year data of VELA-1 and VELA-2 to become available in the second quarter of 2026.
• Expect readout of primary and key secondary endpoints of the IZAR-1 clinical trial (PsA) in the second quarter of 2026.
• Expect readout of primary and key secondary endpoints of the IZAR-2 clinical trial (PsA) in the second half of 2026.
• Expect results of the S-OLARIS trial (axSpA) to become available in the first quarter of 2026.
• Expect topline results for the VELA-TEEN clinical trial (adolescent HS) in the second quarter of 2026.
• Commence a Phase 3 clinical trial in PPP in the third quarter of 2026.
• Submit a first BLA for SLK in the third or fourth quarter of 2026.
• Subject to FDA approval, expect a first commercial launch in the U.S. in 2027.
• Continue to incur significant expenses and operating losses for at least the next three years as development and commercialization preparations continue.
• Continue to attract, hire, and retain additional clinical, scientific, quality control, and administrative personnel.
• Continue refining understanding of SLK/Nanobody biology and potential impact in selected therapeutic indications through non-clinical research.
• Prepare for commercialization of SLK, including establishing sales, marketing, and distribution infrastructure.
• Pursue additional technology transfers and process improvements for manufacturing capabilities.
• Continue extending the global intellectual property portfolio.
• Potentially initiate clinical trials of SLK in other indications beyond HS, PsA, axSpA, and PPP.
• Potentially supplement current strategy with in-licensing or acquisition of additional product candidates.

Key Dates

Recommendation

The filing presents a mixed bag of results. While VELA-1 met its primary endpoint and other trials (ARGO, LEDA, VELA-TEEN) show promise, the failure of VELA-2 to meet its primary endpoint for the lead indication (HS) is a significant setback. This directly impacts the company's ability to draw down additional tranches from its credit facility, reducing committed funding by $175 million. The substantial increase in net loss and R&D expenses reflects aggressive development, but the VELA-2 outcome introduces uncertainty regarding the BLA submission timeline and potential market positioning for SLK in HS. The ongoing class action lawsuit adds another layer of risk. Given the strong results in other indications and the overall potential of SLK, a 'sell' is premature. However, the immediate negative news and increased financial burn warrant caution, suggesting a 'hold' until there is more clarity on the FDA's input for the BLA, the 1-year VELA data, and the outcomes of other pivotal trials.

Keywords

Sonelokimab, SLK, Nanobody, Hidradenitis Suppurativa, HS, Psoriatic Arthritis, PsA, Palmoplantar Pustulosis, PPP, Axial Spondyloarthritis, axSpA, Biotechnology, Clinical Trials, Phase 3, SEC Filing, 10-Q, Immunotherapeutics, Drug Development, Inflammatory Diseases